SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Jonathan Weiss/Shutterstock
Job Trends
AstraZeneca Rare Disease R&D Expansion Adds 500 Jobs At New Hub
On Rare Disease Day, Feburary 28, AstraZeneca announced the creation of the Alexion, AstraZeneca Rare Disease Development Hub in Toronto, Ontario.
February 28, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Aptinyx’ Losing Streak Continues as Parkinson’s Candidate Falls Short
Aptinyx’s NYX-458 fell short of the primary endpoint in a Phase II trial of patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
February 28, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Theravance Cuts JAK Inhibitor, 17% of Workforce in Wake of Shareholder Letter
Theravance Biopharma is discontinuing research activities for its JAK inhibitor program in lung inflammation and reducing its headcount by about 17%.
February 28, 2023
 · 
2 min read
 · 
Tristan Manalac
Pierre Suu/Getty Images
Deals
Seagen has a New Suitor as Pfizer Talks Begin
Seagen and Pfizer are in early-stage talks over a potential acquisition that could exceed $30 billion.
February 27, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Drug Development
Fulcrum’s Clinical Hold Highlights Tough Road in Sickle Cell Space
The hits kept coming for the sickle cell disease space last week as the FDA placed a full clinical hold on Fulcrum Therapeutics’ Investigational New Drug application FTX-6058.
February 27, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Photos
Drug Development
Lilly, Nektar Stumble in Phase II Lupus Trial
Rezpegaldesleukin, Lilly’s and Nektar Therapeutics’ candidate for systemic lupus erythematosus, fell short of its primary efficacy endpoint in the Phase II ISLAND trial.
February 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
Policy
FDA Action Alert: Cytokinetics, Reata, Regeneron, Pfizer and GSK
The FDA is expected to cap off February with a trio of verdicts, including one for a heart failure treatment and another potential first approval for a rare, neurodegenerative disease.
February 24, 2023
 · 
3 min read
 · 
Tristan Manalac
Chesnot/Getty Images
FDA
Sanofi, Sobi Score FDA Nod for Second Hemophilia A Treatment
The FDA approved Sanofi and Sweden-based Sobi’s efanesoctocog alfa, now marketed as Altuviiio, to treat bleeding in adults and children with hemophilia A.
February 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Graphite Bio CEO Josh Lehrer, M.D./courtesy of Gra
Drug Development
Graphite Bio Cuts Sickle Cell Therapy, Half of Staff
Graphite Bio is discontinuing the development of nulabeglogene autogedtemcel (nula-cel), its lead asset, and shaving off about 50% of its workforce.
February 23, 2023
 · 
2 min read
 · 
Tristan Manalac
SKYRIZI is the new option for psoriatic arthritis.
Business
AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases
With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.
February 23, 2023
 · 
2 min read
 · 
Tristan Manalac
Shutterstock
After a Standout IPO and Series of Pivots, Rubius Closes its Doors
Rubius Therapeutics’ board of directors has approved a plan to liquidate and dissolve the company, the Massachusetts-based biotech announced in an SEC form 8-K filed Monday.
February 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
PTC Previews Key Spring Readouts in Full-Year 2022 Report
PTC Therapeutics reported Q4 and full-year 2022 results Tuesday ahead of a pivotal 2023 featuring three late-stage readouts in registration-directed trials.
February 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Actinium’s Targeted Radiotherapy for AML Called “Practice-Changing”
Actinium Pharmaceuticals’ Iomab-B met the primary endpoint in the Phase III SIERRA trial, demonstrating durable Complete Remission at six months.
February 21, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy Tomohiro Ohsumi/Getty Images
Drug Development
Takeda’s Vedolizumab Clears Phase III in aGvHD
Takeda’s vedolizumab met its primary endpoint in the Phase III GRAPHITE study, significantly improving event-free survival in patients with acute graft-versus-host disease.
February 20, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eric Dube, Travere CEO/Company Courtesy
FDA
Travere Scores Accelerated Approval for First Non-Immunosuppressive IgAN Therapeutic
The FDA granted accelerated approval Friday to Travere Therapeutics’ sparsentan, now to be marketed as Filspari, to reduce the burden of proteinuria in adults with primary IgA nephropathy.
February 20, 2023
 · 
2 min read
 · 
Tristan Manalac
Load More